November 8, 2021
Life Sciences
  • Regeneron Pharmaceuticals Inc. said its COVID-19 antibody cocktail offered long-term protection to patients in a late-stage trial. According to the drug manufacturer, there were no hospitalizations for COVID-19 in the REGEN-COV group during the eight-month assessment period. However, six such incidents were recorded in the placebo group. (Article here)